A Golden Opportunity: Pharma Unit for Sale in Baddi, Himachal Pradesh

A running, WHO-GMP certified pharmaceutical manufacturing unit in Baddi (Himachal Pradesh) is available for acquisition at ₹51 crore. This page lays out exactly what you’re buying, why the timing works, what it should earn, and what to verify before you sign — written for a buyer doing real diligence, not a brochure.

The unit at a glance

• Location: Baddi, Himachal Pradesh — 45 min from Chandigarh, 30 min from Panchkula, 4.5 hrs from Delhi
• Land: 3,000 sq m (30,000 sq ft), freehold
• Built-up area: 78,000 sq ft
• Established: 2016
• Facility type: Non-beta-lactam (Tablets, Capsules, Liquid Orals, Ointments)
• Certifications: WHO-GMP, Revised Schedule M (CDSCO), ISO 9001:2015
• Workforce: ~350 trained staff
• Clients: 400+ third-party manufacturing accounts
• Revenue / EBITDA: ₹100+ crore / 15–25% margin (as represented by the seller, subject to due diligence)
• Reason for sale: Owner relocating abroad — a clean, motivated exit rather than a distressed one

Why Baddi

Baddi–Barotiwala–Nalagarh is one of the largest pharmaceutical manufacturing clusters in the country, with 700+ units and a well-developed export base. For a buyer, the value isn’t the postcode — it’s the ecosystem around it:

• Concentrated supply chain — bulk-drug and excipient suppliers, packaging vendors, and pharma-specific equipment service centres are all local, so lead times and downtime are shorter.
• Trained talent pool — three decades of pharma manufacturing means GMP-literate operators, QA/QC analysts, and documentation staff are available without a long hiring-and-training runway.
• Regulatory familiarity — local consultants and licensing authorities handle CDSCO/state processes routinely.

The same unit in a tier-2 industrial zone typically means slower procurement, higher compliance cost, and longer recruitment. Baddi removes those frictions.

The unit in detail

Physical asset

Freehold ownership matters here: as larger players consolidate in Baddi, clear-title freehold plots are getting scarcer, and the land carries independent appreciation potential. The 78,000 sq ft built-up area is sized for efficient operation with room to add lines — you’re not paying for idle space.

Manufacturing capacity

Over 1,000 formulations across four dosage forms. Per 8-hour shift:

The multi-form flexibility is a genuine commercial advantage: if a client shifts from tablets to capsules, or a segment softens, you can re-mix output without a facility change. For a third-party manufacturer, that’s revenue diversification and client-retention insurance.

Certifications & what they actually unlock

An important correction to how WHO-GMP is often pitched: WHO-GMP does not, on its own, open the US, EU, Japan, or Australia. Those highly-regulated markets require their own approvals — USFDA, EU-GMP/EDQM, PMDA, TGA respectively. What WHO-GMP genuinely unlocks is the large set of RoW/semi-regulated markets and the WHO-prequalification and tender pathways. That’s still a substantial, higher-margin expansion beyond commodity domestic supply — it’s just worth stating accurately, because a serious buyer will know the difference.

Business performance (seller-represented)

The figures below are as represented by the seller and must be validated in diligence:

• Revenue: ₹100+ crore/year. At 350 staff, that’s ₹28.6 lakh revenue per employee — within the normal ₹25–35 lakh band for Indian pharma manufacturing, so the unit is adequately staffed, not bloated.
• EBITDA margin: 15–25%. For context, listed third-party-focused manufacturers typically run in the mid-teens to low-twenties, so this range is competitive rather than exceptional. The spread reflects seasonal utilisation and product mix.
• 400+ third-party clients. This is the real moat. Third-party relationships are sticky because switching a product to a new site means re-validation (typically 6–12 months and ₹20–50 lakh for the customer). That structurally protects both retention and modest pricing power.

Why now

1. Third-party manufacturing demand is structural. India is a global hub for generics and APIs, and outsourcing keeps rising — startups avoid ₹2–5 crore capex by using contract manufacturers, and larger firms offload commoditised products to free up capital. A ready unit captures that demand immediately; a greenfield build sits out the first 18–24 months while competitors serve it.

2. Schedule M compliance is now an enforcement reality — and that favours a compliant unit. The revised Schedule M was notified in December 2023 and took effect on 1 January 2025. The extension window for smaller manufacturers closed on 31 December 2025, and CDSCO is now running risk-based inspections with no further blanket extensions signalled. Non-compliant units face retrofits of roughly ₹0.5–1.5 crore per line plus downtime; this facility is already compliant, so that cost and disruption simply don’t apply. As enforcement tightens, compliant capacity gains share.

3. Export headroom via the WHO-GMP pathway. The unit currently exports to a handful of markets (Afghanistan, Sri Lanka, Myanmar, Yemen, Uzbekistan, Nepal, Maldives, Ghana) — a small fraction of what WHO-GMP-accepting markets allow. Expanding into additional RoW/semi-regulated markets, pursuing WHO prequalification on suitable products, and entering tender/donor supply are all realistic growth levers on the existing certification base. (Pricing varies widely by market and product; treat any specific per-unit figures as indicative only.)

The economics

The single most important thing to get right is the return math — and the earlier version of this model got it wrong, so here it is corrected and, better, made interactive.

[INSERT BLOCK 2 HERE — Corrected Financial Tables + Investment Calculator] (the self-contained HTML block with the working ROI/payback calculator)

In short: at the conservative case (₹100 cr revenue, 15% EBITDA, ₹0.75 cr maintenance & compliance), the unit throws off about ₹14.25 crore of unlevered operating cash flow — roughly a 28% cash yield on ₹51 crore, before any leverage. Add leverage and the return on your equity changes; the calculator models debt service correctly (a proper amortising EMI, not a flat estimate) so you can see the real levered picture for your own structure.

On valuation: at ₹18 crore EBITDA (18% midpoint), ₹51 crore is about 2.8× EBITDA — below the 3–4× that comparable units typically fetch. That discount is consistent with a motivated relocation sale rather than a stretched ask, which is part of what makes it worth moving on.

These figures are illustrative, exclude tax and working-capital movements, and do not constitute investment advice. Verify all inputs independently.

Strengths and risks — an honest read

Working in your favour: a proven, diversified client base with high switching costs; multi-dosage flexibility; certifications already in place; a trained workforce you inherit rather than build; and a brownfield asset with no construction or environmental-cleanup unknowns.

What you’re taking on:

None of these is existential with active management — but this is an operating business, not a passive holding.

Due diligence and deal timeline

Before committing capital, verify the fundamentals across five workstreams. Budget roughly ₹20–35 lakh in advisory costs and 4–5 months end to end.

Financial (weeks 3–5): 3 years’ audited P&L reconciled against GST filings and bank statements; cost structure (raw material typically 40–50% of revenue); working-capital ageing; contingent liabilities (tax disputes, litigation, guarantees). Red flag: P&L that doesn’t tie to GST.

Operational (weeks 4–6): independent equipment audit (age, condition, service history — relevant given the 2016 build); capacity validation against actual batch records; QC system and lab adequacy (HPLC, dissolution, method validation per USP/BP); OOS batch history. Red flag: OOS >2%, or nameplate capacity that demonstrated runs don’t support.

Regulatory (week 5): WHO-GMP scope, validity and inspection history; CDSCO licence status and scope; DCGI product approvals; environmental clearances (ETP, hazardous-waste disposal). Red flag: expired certs or open observations.

Customer (weeks 6–7): top-10 concentration (ideally no single client-cluster >50%); contract terms and renewal dates; 5–10 discreet client interviews on quality, reliability, and intent to continue post-sale; churn history. Red flag: >15% annual churn or churn tied to quality.

Legal & ownership (weeks 5–8): title verification (freehold, no encumbrances); ownership/partner authority to sell; change-of-control clauses in customer, supplier, and financing contracts; pending litigation. Red flag: material contracts that terminate on change of control.

Indicative timeline: week 1 initial review → week 2 site visit & management meetings → weeks 3–8 the five workstreams in parallel → weeks 8–10 valuation & negotiation → weeks 10–12 documentation → weeks 12–16 licence transfer, property transfer, and transition. A 30–90 day handover with the outgoing team and key-customer introductions is standard.

Buy this unit, or build new?

Acquisition fits if you want returns inside 3–4 years, can’t wait ~2 years for a build, and value inheriting a working team and client book. Greenfield fits only if you need proprietary IP-specific manufacturing, want to design the plant from scratch, and have deep pharma-operations experience plus a long horizon. For most buyers, acquisition is the lower-risk path.

Is this right for you?

A fit if you have (or will hire) pharma-manufacturing operating capability, can commit ₹51 crore for 5+ years, understand the sector well enough to hold a realistic growth thesis, and are comfortable with solid-but-not-spectacular returns that improve with active management.

Not a fit if you want a passive holding, have no route to operating expertise, need capital liquid across sectors, or expect guaranteed returns — manufacturing offers none.

Next steps

A site visit is essential; you can’t assess a facility from documents alone. Plan a full day — 3–4 hours on the floor (all production areas, QC lab, warehouse, utilities), 2 hours with senior management — and bring an operations advisor and an accountant.

When you make contact, request:

1. Audited financials (last 3 years)
2. WHO-GMP certificate (scope + expiry)
3. CDSCO manufacturing licence (scope + status)
4. Top-20 client list with revenue contribution
5. Equipment schedule (age, condition, maintenance records)
6. Capacity study backed by batch records
7. Environmental-compliance documentation
8. Proposed transition timeline

Contact: Laafon Galaxy Pharmaceuticals — 📞 +91-98124-46733 · ✉️ contact@laafon.com · 📍 Baddi, Himachal Pradesh

Frequently Asked Questions

Figures on this page relating to revenue, EBITDA, and returns are indicative, are as represented by the seller where noted, and are subject to independent verification. Nothing here constitutes an offer, a valuation, or investment advice.